But the drug helped
Plateau responders (initial success followed by stall) You had a great first three to five months
What the Research Shows About Tirzepatide Blood Pressure Effects Clinical studies using both standard office measurements and ambulatory blood pressure monitoring have found that tirzepatide is associated with: Lower average systolic blood pressure Smaller but consistent reductions in diastolic pressure Improvements that become more noticeable over several months On average, systolic blood pressure reductions tend to fall within the midsingle-digit mmHg range, which can be clinically meaningful, particularly for people with obesity-related hypertension

Sources Food and Drug Administration (FDA): FDA Approves New Medication for Chronic Weight Management Molecular Metabolism Journal: Glucagon-like peptide 1 (GLP-1) American Gastroenterological Association (AGA): Biology of Incretins: GLP-1 and GIP Columbia Surgery: The Ozempic Effect: Everything You Need to Know About Medical Weight Loss Eli Lilly: Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies American Diabetes Association (ADA): Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes Important Medical Information and Disclaimers Important Current Status Update : As of March 19, 2025, the FDA has ended enforcement discretion for compounded tirzepatide
Potential Side Effects : While smaller doses might lessen the severity of side effects, its still possible for patients to experience nausea, vomiting, or gastrointestinal discomfort